ELSNER Yan (US),ЭЛЬСНЕР Ян (US),KHARRIS Roj L. (US),ХАРРИС Рой Л. (US),LI Brenden (US),ЛИ Брэнден (US),MORTENSEN Debora (US),МОРТЕНСЕН Дебора (US),PAKARD Garrik (US),ПАКАРД Гаррик (US),PAPA Patrik (US
申请号：
RU2015105249
公开号：
RU0002692796C2
申请日:
2009.10.27
申请国别(地区):
RU
年份:
2019
代理人:
摘要：
FIELD: chemistry.SUBSTANCE: invention relates to use of compounds of formula (I) or (II), where R1 is a substituted phenyl, substituted or unsubstituted heterocyclyl which is an aromatic cycloalkyl containing 6 to 10 atoms in a ring and in which one to two carbon atoms in the cycle are independently substituted on N, where said substitutes are selected from C1-8alkyl, triazolyl, halogen, aminocarbonyl, cyano or hydroxyalkyl； R2 is H, substituted or unsubstituted C1-8alkyl substituted with C3-6cycloalkyl, unsubstituted heterocyclyl, which is a non-aromatic cycloalkyl containing from 5 to 6 atoms in a cycle and in which one to two carbon atoms in the cycle are independently substituted with N or O； unsubstituted heterocyclylalkyl, where heterocyclyl is a non-aromatic cycloalkyl containing 5 to 6 atoms in a ring and in which one to two carbon atoms in the cycle are independently substituted with N and O； substituted or unsubstituted phenylalkyl or substituted or unsubstituted C3-6cycloalkylalkyl, where said substitutes are selected from C1-4alkyl, CF3, OR and NR2, where R is H or C1-4alkyl； R3 and R4, each independently represent H, unsubstituted C1-8alkyl or R3 and R4 together with atom, to which they are attached form C3-6cycloalkyl； or R2 and one of R3 and R4 together with atoms to which they are bonded, form a substituted or unsubstituted heterocyclyl containing from 5 to 6 ring atoms and which may contain an additional heteroatom selected from O； where the substitutes are selected from -C(O)CH2OCN3, -CH2CH2OCN3, OCH3 or CH3； provided that the compound is not 6-(4-hydroxyphenyl)-4-(3-methoxybenzyl)-3,4-dihydropyrazino[2,3-b]pyrazine-2(1H)-one, 6-(4-(1H-1,2,4-triazol-5-yl)phenyl)-3-(cyclohexylmethyl)-3,4-dihydropyrazino[2,3-b]pyrazine-2(1H)-one or (R)-6-(4-(1H-1,2,4-triazol-5-yl)phenyl)-3-(cyclohexylmethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, to obtain a pharmaceutical composition for treating conditions mediated by mTOR kinase, selected from inflammatory c
